JP2023526283A5 - - Google Patents
Info
- Publication number
- JP2023526283A5 JP2023526283A5 JP2022569035A JP2022569035A JP2023526283A5 JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5 JP 2022569035 A JP2022569035 A JP 2022569035A JP 2022569035 A JP2022569035 A JP 2022569035A JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- unsubstituted
- substituted
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025490P | 2020-05-15 | 2020-05-15 | |
| US63/025,490 | 2020-05-15 | ||
| US202063040832P | 2020-06-18 | 2020-06-18 | |
| US63/040,832 | 2020-06-18 | ||
| US202063089419P | 2020-10-08 | 2020-10-08 | |
| US63/089,419 | 2020-10-08 | ||
| US202163160325P | 2021-03-12 | 2021-03-12 | |
| US63/160,325 | 2021-03-12 | ||
| US202163161828P | 2021-03-16 | 2021-03-16 | |
| US63/161,828 | 2021-03-16 | ||
| PCT/US2021/032094 WO2021231653A1 (en) | 2020-05-15 | 2021-05-12 | Mono- and combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526283A JP2023526283A (ja) | 2023-06-21 |
| JP2023526283A5 true JP2023526283A5 (enExample) | 2024-05-17 |
Family
ID=78525230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569035A Pending JP2023526283A (ja) | 2020-05-15 | 2021-05-12 | 単独療法及び併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230210854A1 (enExample) |
| EP (1) | EP4153594A4 (enExample) |
| JP (1) | JP2023526283A (enExample) |
| KR (1) | KR20230010729A (enExample) |
| CN (1) | CN115867551A (enExample) |
| AU (1) | AU2021271844A1 (enExample) |
| BR (1) | BR112022023254A2 (enExample) |
| CA (1) | CA3182270A1 (enExample) |
| IL (1) | IL298201A (enExample) |
| MX (1) | MX2022014131A (enExample) |
| NZ (1) | NZ793883A (enExample) |
| TW (1) | TWI906299B (enExample) |
| WO (1) | WO2021231653A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| CN120475974A (zh) * | 2022-11-08 | 2025-08-12 | 芝诺管理公司 | 阿森色替（azenosertib）在治疗癌症中的间歇性给药方案 |
| TW202502354A (zh) * | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症 |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025226653A1 (en) * | 2024-04-23 | 2025-10-30 | Zeno Management, Inc. | Wee1 inhibitor combination therapy dosing regimen |
| WO2025245463A1 (en) * | 2024-05-23 | 2025-11-27 | Merck Patent Gmbh | Combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703759B2 (en) * | 2016-11-16 | 2020-07-07 | Impact Therapeutics, Inc | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
-
2021
- 2021-05-12 MX MX2022014131A patent/MX2022014131A/es unknown
- 2021-05-12 NZ NZ793883A patent/NZ793883A/en unknown
- 2021-05-12 CN CN202180043458.3A patent/CN115867551A/zh active Pending
- 2021-05-12 BR BR112022023254A patent/BR112022023254A2/pt unknown
- 2021-05-12 US US17/998,561 patent/US20230210854A1/en active Pending
- 2021-05-12 KR KR1020227043881A patent/KR20230010729A/ko active Pending
- 2021-05-12 WO PCT/US2021/032094 patent/WO2021231653A1/en not_active Ceased
- 2021-05-12 AU AU2021271844A patent/AU2021271844A1/en active Pending
- 2021-05-12 JP JP2022569035A patent/JP2023526283A/ja active Pending
- 2021-05-12 CA CA3182270A patent/CA3182270A1/en active Pending
- 2021-05-12 IL IL298201A patent/IL298201A/en unknown
- 2021-05-12 EP EP21803601.0A patent/EP4153594A4/en active Pending
- 2021-05-14 TW TW110117495A patent/TWI906299B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526283A5 (enExample) | ||
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2020525427A5 (enExample) | ||
| ES2275931T3 (es) | Compuestos de aril-urea en combinacion con otros agentes citostaticos o citotoxicos para tratamiento de canceres humanos. | |
| JP2021510376A5 (enExample) | ||
| US20180256578A1 (en) | A Combination Therapy Comprising Varlitinib and an Anticancer Agent | |
| JP2023508332A5 (enExample) | ||
| JP2012523435A5 (enExample) | ||
| JP2023508328A5 (enExample) | ||
| ES2705529T3 (es) | Tratamiento combinatorio del cáncer | |
| JP2024147816A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2022521818A5 (enExample) | ||
| JP2021522197A5 (enExample) | ||
| WO2015142867A1 (en) | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | |
| JP2023507797A5 (enExample) | ||
| US20210220372A1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| JP2025503971A5 (enExample) | ||
| JP7761490B2 (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JP2026506429A (ja) | Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療 | |
| Mir-Bonafé et al. | Adverse hair reactions to new targeted therapies for cancer | |
| CA3121441C (en) | Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug | |
| IL278721B1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | |
| Umesaki et al. | Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study | |
| ES2984592T3 (es) | Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2 | |
| Segawa et al. | A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 |